Drug Database
NI

nilotinib

✓ Approved

MolecularMD · ABL1 · 辅助诊断

什么是 nilotinib?

nilotinib 是一种辅助诊断,由MolecularMD研发。该药已获批,用于治疗相关适应症,给药途径:Others。

药物档案

公司MolecularMD
药物类别辅助诊断
分子靶点ABL1, BCR
给药途径Others
状态Approved

作用机制

分子靶点

nilotinib 作用于 2 个分子靶点:

ABL1ABL proto-oncogene 1, non-receptor tyrosine kinase (c-ABL, bcr/abl)
BCRBCR activator of RhoGEF and GTPase (CML, ALL)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

nilotinib 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Uterine cancer✓ Approved

相关研究文献

PubMedNature2026-11-19

An inspiral of a star inside a common envelope with its giant companion.

Karambelkar Viraj V, De Kishalay K, Temmink Karel D KD, Metzger Brian D BD et al.

The formation of compact stellar binaries requires rapid orbital tightening of their progenitor binary stars1,2. This is theorized to happen through common envelope evolution (CEE)3, when the stars orbit in a loosely bound, shared convective envelope, triggering an inspiral due to frictional drag4,5. However, this inspiral in such a system has never been observed directly. Here we present observations of AT 2025abao, a transient eruption in the Andromeda Galaxy, which originates from the CEE of an approximately 7M⊙ asymptotic giant branch (AGB) star with its companion. Extensive pre- and post-eruption spectroscopy is best explained as an approximately 0.7M⊙ companion inspiralling within the convective AGB envelope that powers a seven-year period of gradual brighteningone of the first direct observations of frictional drag energy dissipation induced by CEE. This phase is radiatively efficient, consistent with predictions for convective transport in CEE5-8. The subsequent merger of the companion with the primary core powers the ejection of the outermost 10% of the stellar envelope at speeds about 10× the primary escape speed, and empirically constrains the fraction of dissipated orbital energy available to unbind the convective common envelope4,9-11, 0.01 ≲ α ≲ 0.4. This end-to-end characterization using multi-survey observations demonstrates a path towards mapping the landscape of CEE outcomes with upcoming surveys.

PMID 43052471
阅读全文 →
PubMedThe oncologist2026-11-19

Long-Term Cardiovascular Adverse Events in Patients with Chronic Myelogenous Leukemia Treated with Tyrosine Kinase Inhibitors.

Zureigat Hadil H, Mohamed Ahmed N AN, Govande Sneha S, Zabor Emily C EC et al.

patients with chronic myelogenous leukemia (CML) treated with tyrosine kinase inhibitors (TKIs) are at risk for cardiotoxicity. Risk estimates from clinical trials may be limited by healthier populations and short follow-up durations. we evaluated the incidence of cardiovascular adverse events (CVD-AE) and echocardiographic changes as a secondary outcome in CML patients on TKIs, accounting for cardiovascular risk from prior TKI exposure. CML patients treated with TKIs at Cleveland Clinic (2007-2022) were included. TKIs analyzed were imatinib, dasatinib, nilotinib, bosutinib, ponatinib, and asciminib. Data included demographics, comorbidities, treatments, and follow-up. Outcomes were overall survival and major adverse cardiovascular events (MACE): acute coronary syndrome (ACS), heart failure, stroke, peripheral arterial disease, and revascularization. Pleural effusions, pericardial effusions and pulmonary hypertension were assessed. Echocardiograms were collected at baseline. Multivariable Cox regression and generalized linear mixed models were applied. among 357 patients (median age 56; 57% male; 85% White), 518 CVD-AE occurred during median follow-up of 7.2 years. Compared with imatinib, nilotinib was associated with increased ACS (HR 3.5, P = 0.02), dasatinib with heart failure (HR 2.5, P = 0.04), and dasatinib, and asciminib with pleural (HRs 3.5, 5.8; P < 0.05) and pericardial effusions (HR 5.1, 21.6; P < 0.05). Dasatinib was associated with lower venous thrombosis (HR 0.1, P = 0.02). MACE incidence did not differ significantly among TKIs. Among 69 patients with serial echocardiograms, ponatinib decreased left ventricular ejection fraction (β = -5.2, P = 0.008) and bosutinib increased global longitudinal strain (β = 3.0, P = 0.037). Cardiovascular risks differ among TKIs, and therapy duration influences echocardiographic changes.

PMID 43053278
阅读全文 →
PubMedBMC ecology and evolution2026-11-19

Herbaceous intercropping reshapes soil microbial communities and induces transcriptomic responses in Morchella.

Gao Zihan Z, Song Qian Q, Yin Wei W, Li Yixin Y et al.

Morchella cultivation faces challenges from continuous cropping obstacles, which are often linked to soil degradation and microbial community shifts. Intercropping has emerged as a potential strategy to mitigate these constraints, yet the ecological mechanisms underlying herbaceous companion plant effects on Morchella remain poorly understood. This study investigated how intercropping with two functionally distinct herbaceous species-Poa pratensis and Vicia sativa-affects Morchella growth, soil microbial assembly, and Morchella transcriptional responses. Three cultivation treatments were established: Morchella monoculture (CK), intercropping with P. pratensis (B), and intercropping with V. sativa (P). Soil physicochemical properties, microbial community composition (16 S rRNA and ITS amplicon sequencing), and Morchella fruiting body transcriptomes (RNA-seq) were analyzed. Intercropping reduced Morchella yield by 23.7% (P treatment) to 36.9% (B treatment) compared with monoculture, yet significantly increased soil available potassium and promoted companion plant growth. Microbial community analysis revealed that intercropping decreased the relative abundance of Ascomycota, particularly Morchella itself (reduced to approximately one-quarter of control levels), while increasing fungal α-diversity and enriching taxa such as Mortierella and Rhizopus. Bacterial communities also shifted, with Pseudomonas abundance increasing 3.3-fold (B) and 3.8-fold (P). Transcriptomic analysis identified 572 upregulated DEGs in the B treatment and 1,090 in the P treatment. Commonly upregulated DEGs were enriched in GO terms related to monocarboxylic acid metabolism, iron ion transport, and carbohydrate binding, and in KEGG pathways including fructose and mannose metabolism and nitrogen metabolism. Treatment-specific responses included enrichment of oxidation-reduction processes in B and symbiont attachment and biofilm formation in P. Continuously upregulated DEGs across the CK-B-P gradient were associated with chromatin assembly and metabolic pathway activation. Herbaceous intercropping reconfigures the Morchella cultivation system by altering soil nutrient availability, reshaping microbial community structure, and inducing adaptive transcriptional responses in the fungus. Although intercropping enhanced soil ecological conditions and microbial functional diversity, it did not translate into yield improvement, suggesting ecological trade-offs between resource competition and environmental optimization. These findings provide a foundation for understanding host-microbe-plant interactions in fungal cultivation systems and highlight the need to balance ecological benefits with productivity outcomes.

PMID 43052735
阅读全文 →
PubMedUltrastructural pathology2026-11-19

A short embedding protocol for diagnostic electron microscopy: long-term implementation and diagnostic outcomes in a high-volume clinical series.

Zhou Hui H, Zhou Xin Jin Joseph XJJ

Epoxy resin polymerization is a lengthy step in tissue preparation for transmission electron microscopy (TEM). We evaluated whether reducing the polymerization step alone to 40 minutes at 120 °C, with upstream processing unchanged, could maintain diagnostic quality. The protocol has been the sole routine method in a high-volume, accredited clinical TEM laboratory for more than 10 years. Among more than 30,000 consecutive cases, no embedding-related diagnostic inadequacy was identified in consultant pathologist sign-out records. In a prospective, blinded, split-specimen comparison of renal biopsies, both pathologists scored 4 or 5 on every feature for both methods. Nearly all scores were at the upper end of the scale, indicating comparable performance but not establishing statistical equivalence. Glomerular basement membrane thickness was closely similar (mean difference -12.7 nm, ~4%), within measurement variability and below diagnostic detection thresholds. Because curing behavior depends on the resin formulation and oven conditions, local validation is required before implementation.

PMID 43053495
阅读全文 →
PubMedCommunications medicine2026-11-19

A systematic review of the prevalence and diagnostic approaches of respiratory sarcopenia.

Teixeira Leonardo Augusto da Costa LADC, Soares Luana Aparecida LA, Mourão Maria Fernanda Dos Santos MFDS, Nobre Juliana Nogueira Pontes JNP et al.

Respiratory sarcopenia (RS) is a recently described condition characterized by the coexistence of sarcopenia and respiratory dysfunction. In addition to the physical consequences of sarcopenia, RS is accompanied by respiratory dysfunction, potentially increasing aging-related functional decline. However, its prevalence and diagnostic approaches remain unclear, and no global consensus has been established. This study systematically reviews the prevalence and diagnostic approaches of RS. We conducted a systematic review following the Preferred Reporting Items for Systematic Reviews and Meta Analyses 2020 guidelines. Searches were performed in PubMed, Scopus, EMBASE, Lilacs, and SciELO in October 2025 using the term "respiratory sarcopenia" without filters. Quantitative synthesis included only cross-sectional, cohort, and longitudinal studies. Data on study characteristics, diagnostic methods, and prevalence were extracted, and risk of bias was assessed using the Joanna Briggs Institute critical appraisal tool. Here we show that 27 studies involving 31,210 predominantly older adults were included, revealing an estimated global RS prevalence of 18.7%. Estimated prevalence is 18.8% in older adults, 17.1% in non-older populations, and 75.8% in populations with secondary conditions. Studies using the JARN recommendations report higher prevalence than those using the criteria proposed by Kera et al. Substantial heterogeneity remains, particularly regarding assessment methods. RS is a prevalent but inconsistently defined condition, and current evidence is limited by diagnostic heterogeneity. A global consensus may improve diagnostic standardization, comparability across studies, and future clinical applications.

PMID 43052480
阅读全文 →
PubMedNPJ genomic medicine2026-11-19

Genome sequencing based sequential diagnostic strategy improve diagnosed yield of pediatric genetic kidney disease: a national multicenter study.

Wang Chunyan C, Tang Xiaoshan X, Wang Xiuli X, Sun Shuzhen S et al.

Genetic kidney disease (GKD) is a major cause of pediatric chronic kidney disease. Many patients remain genetically unresolved by exome sequencing (ES) and copy number variation (CNV) analysis. Genome sequencing (GS) enables a comprehensive detection of genetic variations. This study evaluates a GS-based sequential strategy to determine the diagnostic yield in pediatric GKD. We recruited families with GKD from a national cohort of 23 centers from 2020 to 2024 through Chinese Children Genetic Kidney Disease Database. This sequential sequencing strategy involved initial trio-ES and Trio-CNV-seq, followed by GS in undiagnosed cases, splicing essays analysis was performed for intronic variants. A total of 735 families were enrolled. Trio-ES and Trio-CNV-seq achieved a diagnostic yield of 39.4% (35.5% from ES and 4.0% from CNV-seq). Subsequent GS identified pathogenic variants in 23 of 445 previously undiagnosed cases (5.2%), including small structural variants (5 cases), intronic variants affecting splicing function (9 cases), and variants in mitochondrion DNA (9 cases). GS showed 14% and 8.8% increase in diagnostic yield in renal tubular disease and CKD of unexplained cause. Syndromic cases exhibited a higher diagnostic yield (10.9%) than isolated cases (4.6%). These findings indicate GS-based sequential strategy improves the diagnostic yield of GKD.

PMID 43052312
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多nilotinib